Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5935/0103-507X.20200060 http://scihub22266oqcxt.onion/10.5935/0103-507X.20200060 32965395!7595725!32965395     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Bras+Ter+Intensiva 2020 ; 32 (3): 337-347 Nephropedia Template TP {{tp|p=32965395|t=2020. Justificativa e delineamento do estudo "Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicentrico, randomizado, controlado" (TOCIBRAS) |pdf=|usr=}}{{32965395}} gab.com Text Justificativa e delineamento do estudo "Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicentrico, randomizado, controlado" (TOCIBRAS) JO: Rev Bras Ter Intensiva http://www.kidney.de/pget.php?&tw=1&pmid=32965395 #FOAvip INTRODUCTION: Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients. We designed a trial testing tocilizumab versus standard of care intending to improve the outcomes by inhibiting interleukin-6, an important inflammatory mediator in COVID-19. METHODS AND ANALYSIS: This open-label multicentre randomized controlled trial will compare clinical outcomes of tocilizumab plus standard of care versus standard of care alone in patients with moderate to severe COVID-19. Two of the following four criteria are required for protocol enrolment: D-dimer > 1,000ng/mL; C reactive protein > 5mg/dL, ferritin > 300mg/dL, and lactate dehydrogenase > upper limit of normal. The primary objective will be to compare the clinical status on day 15, as measured by a 7-point ordinal scale applied in COVID-19 trials worldwide. The primary endpoint will be assessed by an ordinal logistic regression assuming proportional odds ratios adjusted for stratification variables (age and sex). ETHICS AND DISSEMINATION: The TOCIBRAS protocol was approved by local and central (national) ethical committees in Brazil following current national and international guidelines/directives. Each participating center had the study protocol approved by their institutional review boards before initiating protocol enrolment. The data derived from this trial will be published regardless of the results. If proven active, this strategy could alleviate the consequences of the inflammatory response in COVID-19 patients and improve their clinical outcomes. Twit Text FOAVip Justificativa e delineamento do estudo "Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicentrico, randomizado, controlado" (TOCIBRAS) ????Rev Bras Ter Intensiva http://www.kidney.de/pget.php?&tw=1&pmid=32965395 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32965395 #FOAvip English Wikipedia <ref>{{Cite pmid|32965395}}</ref> Justificativa e delineamento do estudo "Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicentrico, randomizado, controlado" (TOCIBRAS) #MMPMID32965395 Farias DLC; Prats J; Cavalcanti AB; Rosa RG; Machado FR; Berwanger O; Azevedo LCP; Lopes RD; Avezum A; Kawano-Dourado L; Damiani LP; Rojas SSO; Oliveira CZ; Andrade LEC; Sandes AF; Pintao MC; Castro Junior CG; Scheinberg P; Veiga VC Rev Bras Ter Intensiva 2020[Jul]; 32 (3): 337-347 PMID32965395show ga INTRODUCTION: Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients. We designed a trial testing tocilizumab versus standard of care intending to improve the outcomes by inhibiting interleukin-6, an important inflammatory mediator in COVID-19. METHODS AND ANALYSIS: This open-label multicentre randomized controlled trial will compare clinical outcomes of tocilizumab plus standard of care versus standard of care alone in patients with moderate to severe COVID-19. Two of the following four criteria are required for protocol enrolment: D-dimer > 1,000ng/mL; C reactive protein > 5mg/dL, ferritin > 300mg/dL, and lactate dehydrogenase > upper limit of normal. The primary objective will be to compare the clinical status on day 15, as measured by a 7-point ordinal scale applied in COVID-19 trials worldwide. The primary endpoint will be assessed by an ordinal logistic regression assuming proportional odds ratios adjusted for stratification variables (age and sex). ETHICS AND DISSEMINATION: The TOCIBRAS protocol was approved by local and central (national) ethical committees in Brazil following current national and international guidelines/directives. Each participating center had the study protocol approved by their institutional review boards before initiating protocol enrolment. The data derived from this trial will be published regardless of the results. If proven active, this strategy could alleviate the consequences of the inflammatory response in COVID-19 patients and improve their clinical outcomes. |*Anti-Inflammatory Agents/pharmacology/therapeutic use[MESH] |*Antibodies, Monoclonal, Humanized/pharmacology/therapeutic use[MESH] |*COVID-19[MESH] |*COVID-19 Drug Treatment/methods[MESH] |Brazil[MESH] |Humans[MESH] |Interleukin-6/antagonists & inhibitors[MESH] |Multicenter Studies as Topic[MESH] |Pandemics[MESH] |Randomized Controlled Trials as Topic[MESH]Justificativa e delineamento do estudo "Tocilizumabe em pacientes com (epmc).pdf DeepDyve Pubget Overpricing